Rita Miguel

Rita Miguel

Auto-generated profile, based on publicly available information

Rita Miguel

Neurology Department, Hospital Egas Moniz – Centro Hospitalar Lisboa Ocidental, Lisbon

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Frontiers in Neurology
Verified
Journal Article
Open access
LALuísa Alves
Luísa Alves
ACAna Sofia A. Correia
Ana Sofia A. Correia
RMRita Miguel
Rita Miguel
PAPaulo Alegria
Paulo Alegria
PBPaulo Bugalho
Paulo Bugalho
Investigation in the field of Alzheimer’s disease (AD), the commonest cause of dementia, has been very active in recent years and it may be difficult for the clinician to keep up with all the innovations and to be aware of the implications they have in clinical practice. The authors, thus, reviewed recent literature on the theme in order to provide the clinician with an updated overview, intended to support decision-making on aspects of diagnosis and management. This article begins to focus on the concept of AD and on its pathogenesis. Afterward, epidemiology and non-genetic risk factors are approached. Genetics, including genetic risk factors and guidelines for genetic testing, are mentioned next. Recommendations for diagnosis of AD, including recently proposed criteria, are then reviewed. Data on the variants of AD is presented. First approach to the patient is dealt with next, followed by neuropsychological evaluation. Biomarkers, namely magnetic resonance imaging, single photon emission tomography, FDG PET, PiB PET, CSF tau, and Aβ analysis, as well as available data on their diagnostic accuracy, are also discussed. Factors predicting rate of disease progression are briefly mentioned. Finally, non-pharmacological and pharmacological treatments, including established and emerging drugs, are addressed.

20 January 2013 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
PBPaulo Bugalho
Paulo Bugalho
LALuísa Alves
Luísa Alves
RMRita Miguel
Rita Miguel

1 March 2014 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
PBPaulo Bugalho
Paulo Bugalho
LALuísa Alves
Luísa Alves
RMRita Miguel
Rita Miguel
OROlga Ribeiro
Olga Ribeiro

1 November 2014 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
RMRita Miguel
Rita Miguel
MGMiguel Fernandes Gago
Miguel Fernandes Gago
JMJoão Martins
João Martins
PBPedro Barros
Pedro Barros
JVJosé Vale
José Vale
MRMaria José Rosas
Maria José Rosas

21 November 2016 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
RMRita Miguel
Rita Miguel
MMMarcelo Mendonça
Marcelo Mendonça
RBRaquel Barbosa
Raquel Barbosa
FLFilipa Ladeira
Filipa Ladeira
TLTânia Lampreia
Tânia Lampreia
PBPaulo Bugalho
Paulo Bugalho
Tetrabenazine (TBZ) is commonly used in hyperkinetic movement disorders. In this retrospective study, we aimed to assess the TBZ effectiveness and adverse events (AEs) in Huntington disease (HD), vascular chorea, tics, dystonia, tardive oromandibular (OM) dyskinesia and other tardive syndromes (TS). Qualitative analysis of clinical response was used to estimate TBZ effectiveness. TBZ-associated AE frequency and subsequent discontinuation rate were used to estimate tolerability; the tolerability profile was measured through the TBZ minimal dose and exposure time required to elicit AEs. Of 108 included patients, 87% had a clinically meaningful improvement sustained over a period of 40 months. TBZ-responder rate ranged from 100% in HD to 62.5% and 77.1% in tic disorders and OM dyskinesia, respectively (p < 0.001). TBZ-associated AE frequency ranged from 40.9% in other TS and 41.7% in vascular chorea and HD, to 60% in OM dyskinesia (p < 0.001). The most common AEs were Parkinsonism (51.8%) and psychiatric disorders (25%). The ‘other AEs’ category (mainly somnolence) presented the shortest minimal exposure time (3 months). AE-eliciting dose differed from 18.8 mg and 25 mg in tics and tardive disorders, to 75 mg in HD (p = 0.003). Patients with AEs were tendentiously older at TBZ initiation (p = 0.022). TBZ proved an effective and relatively well tolerated treatment in hyperkinetic disorders, with excellent results in HD. AEs were more common in OM dyskinesia, which may be related to higher age at TBZ initiation. TBZ-associated somnolence and Parkinsonism were more frequent during the titration and maintenance periods, respectively.

17 March 2017 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
MMMarcelo Mendonça
Marcelo Mendonça
TLTania Lampreia
Tania Lampreia
RMRita Miguel
Rita Miguel
ACAndré Caetano
André Caetano
RBRaquel Barbosa
Raquel Barbosa
PBPaulo Bugalho
Paulo Bugalho